Key Takeaways
- • Rapport Therapeutics announced public offerings of $200 million in common stock and $150 million in convertible senior notes, with options for additional shares and notes.
- • Proceeds are earmarked for clinical trials of lead drug RAP-219, research and development, and general corporate purposes.
- • A concurrent private placement with a separate investor is also planned, and all offerings are subject to market conditions.
- • The raise supports Rapport's precision neuroscience pipeline targeting neurological and psychiatric disorders.
Summary
Rapport Therapeutics has launched public offerings totaling $350 million, comprising $200 million in common stock and $150 million in convertible senior notes, according to the company's announcement as reported by Pluang. Both offerings carry options for additional shares and notes, which could expand the total raise if exercised.
The company intends to deploy the proceeds primarily to fund clinical trials for RAP-219, its lead drug candidate, alongside research and development activities and general corporate purposes. A concurrent private placement with a separate investor is also planned. The offerings are subject to prevailing market conditions, and no pricing terms were included in the source material.
The financing supports Rapport's precision neuroscience pipeline, which targets neurological and psychiatric disorders. The capital raise positions the company to advance its clinical programs as it moves its lead asset through trials.
Pluang's coverage also included a market snapshot as of October 28, 2026, at 03:11 WIB, showing 88 of 150 priced US health-sector stocks rising and 62 falling. Ginkgo Bioworks, Butterfly Network and ImmunityBio were among the notable movers that day, though these figures are not directly tied to Rapport's offering.
The company intends to deploy the proceeds primarily to fund clinical trials for RAP-219, its lead drug candidate, alongside research and development activities and general corporate purposes. A concurrent private placement with a separate investor is also planned. The offerings are subject to prevailing market conditions, and no pricing terms were included in the source material.
The financing supports Rapport's precision neuroscience pipeline, which targets neurological and psychiatric disorders. The capital raise positions the company to advance its clinical programs as it moves its lead asset through trials.
Pluang's coverage also included a market snapshot as of October 28, 2026, at 03:11 WIB, showing 88 of 150 priced US health-sector stocks rising and 62 falling. Ginkgo Bioworks, Butterfly Network and ImmunityBio were among the notable movers that day, though these figures are not directly tied to Rapport's offering.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.